Business Wire (Mon, 3-Aug 10:07 AM ET)
PRNewswire (Fri, 31-Jul 10:07 AM ET)
Raymond James Sticks to Its Buy Rating for Phathom Pharmaceuticals (PHAT)
TipRanks (Fri, 31-Jul 8:58 AM ET)
TipRanks (Fri, 31-Jul 6:27 AM ET)
PRNewswire (Thu, 30-Jul 5:35 PM ET)
Analysts’ Top Healthcare Picks: Tvardi Therapeutics (TVRD), Disc Medicine (IRON)
TipRanks (Thu, 30-Jul 2:10 PM ET)
Here are the major earnings after the close Thursday
Seeking Alpha News (Thu, 30-Jul 10:00 AM ET)
Market Chameleon (Thu, 30-Jul 5:14 AM ET)
Phathom Pharmaceuticals Non-GAAP EPS of $0.00 beats by $0.10, revenue of $74.27M beats by $1.58M
Seeking Alpha News (Thu, 30-Jul 7:29 AM ET)
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 30-Jul 6:59 AM ET)
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Phathom Pharmaceuticals trades on the NASDAQ stock market under the symbol PHAT.
As of August 3, 2026, PHAT stock price climbed to $9.03 with 577,038 million shares trading.
PHAT has a beta of 1.33, meaning it tends to be more sensitive to market movements. PHAT has a correlation of 0.07 to the broad based SPY ETF.
PHAT has a market cap of $730.54 million. This is considered a Small Cap stock.
Last quarter Phathom Pharmaceuticals reported $74 million in Revenue and $.00 earnings per share. This beat revenue expectation by $745,104 and exceeded earnings estimates by $.11.
In the last 3 years, PHAT traded as high as $19.71 and as low as $2.21.
The top ETF exchange traded funds that PHAT belongs to (by Net Assets): VTI, IWM, VXF, XPH, IBB.
PHAT has underperformed the market in the last year with a price return of +5.7% while the SPY ETF gained +20.8%. PHAT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -19.4% and -17.5%, respectively, while the SPY returned +5.5% and +1.7%, respectively.
PHAT support price is $8.39 and resistance is $9.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PHAT shares will trade within this expected range on the day.